Time after starting anti-TNF-α therapy | ||||
---|---|---|---|---|
T0 (baseline) | T1 (3 months) | T2 (9 months) | T3 (15 months) | |
Women with RA, n (%) | 29 (100) | |||
Age (years), mean (SD) | 44.38 (14.17) | |||
Disease duration (years), median (IQR) | 5 (3–8) | |||
BMI (kg/m2), mean (SD) | 21.25 (2.28) | |||
RF positive, n (%) | 29 (100) | |||
Anti-CCP positive, n (%) | 29 (100) | |||
SJC28, median (IQR) | 6 (5–10) | 3 (2–3)a, c, d | 0 (0–1)a, b | 0 (0–0)a, b |
TJC28, median (IQR) | 14 (10–20) | 5 (3–7)a, c, d | 2 (1–2)a, b, d | 0 (0–1)a, b, c |
VAS, median (IQR) | 80 (80–80) | 50 (35–55)a, c, d | 25 (10–30)a, b, d | 10 (5–20)a, b, c |
DAS28 ESR, mean (SD) | 5.99 (0.50) | 4.00 (0.73)a, c, d | 2.74 (0.72)a, b, d | 2.06 (0.64)a, b, c |
Disease activity, n (%) | ||||
High (> 5.1) | 29 (100) | 2 (6.90) | 0 | 0 |
Moderate (> 3.2 and ≤ 5.1) | 0 | 24 (82.76) | 6 (20.69) | 0 |
Low (≤ 3.2 and > 2.6) | 0 | 3 (10.34) | 12 (41.38) | 6 (20.69) |
Remission (≤ 2.6) | 0 | 0 | 11 (37.93) | 23 (79.31) |
ESR (mm/h), median (IQR) | 15.0 (10.0–31.0) | 10.0 (8.0–17.0) | 10.0 (8.0–14.0)a | 11.0 (8.0–14.0)a |
CRP (mg/l), median (IQR) | 5.0 (4.0–9.2) | 4.0 (2.0–4.0) | 3.0 (1.30–4.0)a | 2.0 (1.0–4.0)a |
TNFαI therapy, n (%) | ||||
Etanercept (Enbrel) | 13 (44.83) | |||
Adalimumab (Humira) | 14 (48.27) | |||
Certolizumab pegol (Cimzia) | 2 (6.90) |